We then evaluated whether serum derived from patients could reduce NLRP12 levels in cells because serum derived from SLE patients with elevated IFN-I bioactivity can induce the expression of ISGs through the cGAS/STING pathway (3). The gene discussed is CGAS; the disease is systemic lupus erythematosus.